Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 7/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.32 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.32 |
| ▸ | AGXT | P21549 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL358582 | 1.00 | ACHE (0.44) | ACHETDP1CA1CA2CA7 | |
| SCHEMBL1645074 | 1.00 | ACHE (0.44) | ACHETDP1CA1CA2CA7 | |
| SCHEMBL22106133 | 0.78 | PARP10 (0.54) | ALDH1A1AGXT | |
| SCHEMBL563967 | 0.77 | ACHE (0.50) | ACHETDP1CA1CA2CA7 | |
| SCHEMBL235851 | 0.77 | ACHE (0.50) | ACHETDP1CA1CA2CA7 | |
| SCHEMBL4401131 | 0.77 | ACHE (0.50) | ACHETDP1CA1CA2CA7 | |
| SCHEMBL12903527 | 0.74 | MEN1 (0.47) | ACHETDP1CA1CA2CA7 | |
| SCHEMBL254471 | 0.74 | ACHE (0.47) | ACHETDP1CA1CA2CA7 | |
| SCHEMBL280535 | 0.74 | ACHE (0.47) | ACHETDP1CA1CA2CA7 | |
| SCHEMBL1094237 | 0.74 | ACHE (0.47) | ACHETDP1CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108963389-A | It is a kind of for lithium-air battery can gelling system and its preparation method and application | 北京师范大学 | 2018-12-07 | — | — | CN | claimed |
| US-12606572-B2 | Substituted heterocycles and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4724445-A1 | SUBSTITUTED HETEROCYCLES AND USES THEREOF | Kumquat Biosciences Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| WO-2026041636-A1 | MACROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2026-02-26 | — | — | WO | disclosed |
| EP-4615823-A2 | COMPOUNDS, COMPLEXES, AND METHODS FOR THEIR PREPARATION AND OF THEIR USE | Revolution Medicines, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20250269037-A1 | COMPOUNDS, COMPLEXES, AND METHODS FOR THEIR PREPARATION AND OF THEIR USE | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-08-28 | — | — | US | disclosed |
| US-12252497-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2025-03-18 | — | — | US | disclosed |
| US-20250074923-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-03-06 | — | — | US | disclosed |
| US-12202845-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2025-01-21 | — | — | US | disclosed |
| WO-2024254334-A1 | SUBSTITUTED HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| CN-101356161-A | Heterocyclic CETP inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2009-01-28 | — | — | CN | disclosed |
| CN-101312939-A | Heterocyclic cetp inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2008-11-26 | — | — | CN | disclosed |
| CN-101263156-A | Novel macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE INC (US) | 2008-09-10 | — | — | CN | disclosed |
| EP-1954668-A2 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | Brystol-Myers Squibb Company (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1951690-A1 | HETEROCYCLIC CETP INHIBITORS | Brystol-Myers Squibb Company (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| WO-2007062308-A2 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007062342-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | ARRAY BIOPHARMA, INC. | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606572-B2 | Substituted heterocycles and uses thereof | KRAS, HRAS, MYC | ACHE 4842/4885TDP1 3835/4885CA1 1967/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | ACHE 3249/4885TDP1 610/4885CA1 4507/4885 |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | ACHE 3249/4885TDP1 610/4885CA1 4507/4885 |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | EIF2AK2, HAVCR2, HCCS | ACHE 4019/4885TDP1 4489/4885CA1 4665/4885 |
| US-20250074923-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | ACHE 4585/4885TDP1 4264/4885CA1 4678/4885 |
| US-12252497-B2 | Ras inhibitors | KRAS, NRAS, HRAS | ACHE 4585/4885TDP1 4264/4885CA1 4678/4885 |
| US-20250269037-A1 | COMPOUNDS, COMPLEXES, AND METHODS FOR THEIR PREPARATION AND OF THEIR USE | PAICS, ORC3, SSB | ACHE 157/4885TDP1 3916/4885CA1 368/4885 |
| US-12202845-B2 | Ras inhibitors | KRAS, NRAS, HRAS | ACHE 4585/4885TDP1 4264/4885CA1 4678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.